FDA green light setup 👀

*This email contains promotional content

Hey folks,

Futures were basically flat Sunday night as traders sized up the latest headlines out of the Middle East.

The S&P and Nasdaq are sitting near all-time highs after a strong run last week, while the Dow lagged a bit. At the same time, there’s still a lot of uncertainty around how things are unfolding overseas, and we’ve got a big jobs report coming Friday that could shake things up.

In other words, the market is stretched… and a little on edge.

While there’s understandably a lot of focus on mega-cap tech and AI, it’s a great time to focus on small-cap gems as well.

Right now I’m locked in on a small-cap biotech that just dropped a major update late last week… one that could completely change the trajectory of the company.

We’re talking about clear alignment with the FDA on a pivotal study, the kind that can open the door to both accelerated approval and full approval in one shot.

The underlying clinical data hasn’t been just “good.”

In multiple cases, it’s coming in at double or even triple what’s been seen historically.

On top of that, this company is working alongside some of the biggest names in pharma, the kind of partners that don’t get involved unless the science is promising.

Add in multiple fast-track designations from the FDA, a fresh move into the U.S. to attract institutional capital, and analyst targets that suggest significant upside from current levels…

…and you’ve got the kind of setup that can start moving quickly once it gets discovered.

👉 See What I’m Watching Before the Open 👈

This is not a crowded trade yet.

But the pieces are starting to line up, and if momentum builds, it doesn’t take much for a stock like this to make a sharp move in a short period of time.

That’s why I want you to look at this one before the bell.

👉 Get the Full Breakdown Here 👈

To Your Success,

P.S. -⚡Daily Action in our Momentum Stock Trading Room from 9am - 4pm ET  

(ALL are welcome)